PRPS1P2

Across TCGA pan-cancer cohorts, PRPS1P2 RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated PRPS1P2 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PRPS1P2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRPS1P2 expression acts as an unfavorable survival marker, although some lineages such as SKCM and PAAD show a favorable association.

STAD, SKCM, and MESO are the cancer types where PRPS1P2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	III,IV	0.302	0.668	<.001	59	view →
SKCM	OS	Median	III,IV	0.502	0.283	.002	39	view →
MESO	DFS	Median	All	0.235	0.611	.002	30	view →
KIRC	DFS	Median	All	0.766	0.841	.017	29	view →
PAAD	OS	Median	All	0.576	0.332	.002	27	view →
CESC	DFS	Quartile	III,IV	0.226	0.932	.003	24	view →
UCS	DFS	Tertile	III,IV	0.396	0.137	.025	20	view →
BLCA	DFS	Tertile	All	0.194	0.553	.001	19	view →
ESCA	OS	Median	IV	0.222	0.698	.006	18	view →
COAD	OS	Median	All	0.732	0.870	.004	16	view →
THCA	OS	Quartile	II,III,IV	0.723	1.000	.003	15	view →
LUSC	DFS	Tertile	III,IV	0.685	1.000	.016	15	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

PRPS1P2–STAD (DFS)

Open the STAD breakdown →